Effects of a Dietary Fibre Supplementation of a Low Calorie Diet on Appetite and Body Weight

Sponsor
Canadian Center for Functional Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT01109199
Collaborator
University of British Columbia (Other), InovoBiologic Inc. (Industry)
20
2
2
8
10
1.3

Study Details

Study Description

Brief Summary

This 18 week, randomized, double blind, placebo controlled trial will examine the effects of thick dietary fibre (PGX) supplementation of a low calorie diet (LCD) on appetite, weight loss, body composition, and compliance in overweight and moderately obese female.

The investigators believe that 15 grams/day PGX supplementation of a low calorie diet over a 14-weeks period will elicit a better appetite score (e.g. reduced hunger) compared to the rice flour supplementation of the LCD.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: PolyGlycopleX (PGX)
  • Dietary Supplement: Rice flour
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a High Viscosity Dietary Fibre (PGX) Supplementation of a Low Calorie Diet on Appetite and Body Weight, in Overweight and Moderately Obese Females
Study Start Date :
Aug 1, 2010
Actual Primary Completion Date :
Apr 1, 2011
Actual Study Completion Date :
Apr 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: PolyGlycopleX (PGX)

Dietary Supplement: PolyGlycopleX (PGX)
The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.

Placebo Comparator: Rice Flour

Dietary Supplement: Rice flour
The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.

Outcome Measures

Primary Outcome Measures

  1. The difference in appetite score assessed from appetite Visual Analog Scale [18 weeks]

Secondary Outcome Measures

  1. Change in weight (kilograms) [18 weeks]

  2. Change in percentage of body fat [18 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 55 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • BMI 25 - 35 Kg/m2
Exclusion Criteria:
  • Medications and supplements that affect appetite

  • Known diabetes

  • Contraindications to LCD

  • Any other medical, social or geographic condition, which, in the opinion of the investigator would not allow safe completion of the protocol.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Canadian Center for Functional Medicine Coquitlam British Columbia Canada V3K 6Y7
2 Canadian Center for Functional Medicine Coquitlam British Columbia Canada

Sponsors and Collaborators

  • Canadian Center for Functional Medicine
  • University of British Columbia
  • InovoBiologic Inc.

Investigators

  • Principal Investigator: Michael R Lyon, M.D., Canadian Center for Functional Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Canadian Center for Functional Medicine
ClinicalTrials.gov Identifier:
NCT01109199
Other Study ID Numbers:
  • PGX RCT Study
First Posted:
Apr 23, 2010
Last Update Posted:
Oct 2, 2015
Last Verified:
Sep 1, 2015
Keywords provided by Canadian Center for Functional Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 2, 2015